Accuray offers highly asymmetric turnaround upside from a 0.5x EV/Sales valuation, but dilution, weak orders, leverage, and execution risk make ARAY a distressed speculative restructuring play.
Overview
Accuray designs and supports precision radiation-oncology systems, combining cyclical product placements with recurring, high-margin service revenue. Its CyberKnife robotic SRS/SBRT platform and Radixact tomographic system are differentiated by sub-millimeter treatment, Synchrony real-time motion tracking, and ClearRT imaging, while software integration and specialized training create high switching costs. **The installed-base service stream is the key defensive asset**, rising to 57% of fiscal 2026 revenue from 49% and growing 3.8% for the year to $229.23 million. The financial trajectory remains distressed: fiscal 2026 revenue fell 12.3% to $401.94 million, adjusted EBITDA declined 62.5% to $10.60 million, and GAAP net loss widened to $49.19 million. Q4 showed some operating leverage, with 34.8% gross margin and $12.90 million adjusted EBITDA, but product revenue fell 42.2%. TCW’s recapitalization would reduce net debt to $86.2 million and provide a covenant holiday through December 2027, at the cost of potential 87% share dilution. At $0.295, the stock trades at 0.39x trailing EV/Sales versus Elekta at 1.2x. **The near-term catalysts are shareholder approval on October 6, 2026, phase-two savings, order stabilization, and partnership execution.**